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Background: More than 50% of patients with esophageal cancer are not suitable for surgery. 
The aim of this study was to analyze the outcome of patients undergoing standard nonsurgical 
treatment.
Methods: Data of all patients undergoing nonsurgical treatment for esophageal cancer were 
identified from a prospective database.
Results: Seventy-five patients were treated for localized disease, and 52 for metastatic disease 
at diagnosis. Except for age, which was higher in patients without metastases, there were no 
significant differences between the patients with vs. without metastatic disease. Kaplan–Meier 
analysis showed a median survival of 10.8 months for all patients. There was a significant 
difference in survival (p  0.001) between the groups with versus without metastases, with 
median survival in the patients without metastases 13.6 months versus 6.5 months in patients 
with metastases. Patients undergoing nonsurgical treatment for localized disease had a five-
year survival of 12%. No significant difference between adenocarcinoma and squamous cell 
carcinoma was identified. Subanalysis of patients who received chemoradiotherapy revealed 
similar results to the overall group of patients.
Conclusion: In patients with localized disease at diagnosis, long-term survival can be achieved 
in some patients, whereas five-year survival is rare in patients who present with metastatic 
disease.
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Introduction
Worldwide, esophageal cancer is the sixth leading cause of death from cancer. While the 
incidence of adenocarcinoma is increasing, the incidence of squamous cell carcinoma 
(SCC) is stable.1 The cornerstone of curative treatment has been surgery. However, for 
a variety of reasons, the majority of patients with esophageal cancer are actually not 
suitable for esophagectomy. More than 50% have locally advanced, unresectable or 
metastatic tumors at diagnosis.2 Other reasons which preclude esophagectomy include 
old age, comorbidity, or refusal by the patient.3
The mainstay of nonsurgical treatment is chemotherapy (CT) or radiotherapy (RT), 
either alone or in combination (chemoradiotherapy; CRT). In comparative studies 
which included patients with International Union against Cancer (UICC) stages I 
to III, combined therapy has been shown to be more effective than single modality 
therapy.4–6 Only one study has shown no advantage for CRT compared to RT.7 Clinical and Experimental Gastroenterology 2009:2 76
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Other noncomparative studies excluding UICC stage IV 
patients have shown two-year survival rates of up to 26%, 
whereas UICC stage IV patients are reported to have median 
survival of between 5 and 12 months following these treat-
ments.8–13
Standard CRT treatment usually entails 5-fluorouracil 
(5-FU) and cisplatin in variable dosages, combined with 
50 to 64 Gy of radiation.6 However, a substantial number of 
other agents such as docetaxel, capecitabine, or bortezomib 
have been tested in the settings of advanced or metastatic 
esophageal cancer.9,11,12 The groups of patients studied in 
various clinical trials differ in terms of stage and histological 
subtype. Additionally, most reports only describe small 
numbers of patients, and many of the studies were funded by 
the manufacturers of the CT agents evaluated in these studies. 
These factors make it difficult to know the actual outcome 
for nonsurgical treatment in day to day clinical practice, ie, 
outside clinical trials.
A number of factors have been shown to predict survival 
in advanced esophageal cancer. These include UICC stage, 
performance status, weight loss, and presence or absence 
of metastasis. The stage of the cancer, and in particular 
the presence of metastatic disease, is the single strongest 
predictor.14,15 The influence of other factors, such as histo-
logical type, has been less well established.2,16
Many previous studies have reported outcomes for 
patients undergoing surgical resection for esophageal can-
cer. However, the outcome of such studies does not inform 
clinical decision making for the majority of patients who 
present to surgeons with esophageal cancer. Hence, in this 
study we sought to determine the outcome for patients who 
underwent treatment of esophageal cancer with conventional 
CT and RT, but not surgical resection, in our departments. 
We also determined the specific outcomes for patients with 
and without metastatic disease, and in patients with different 
histological subtypes.
Patients and methods
From 1999 onwards, details for patients with esophageal 
cancer in two university hospitals and associated private 
hospitals in South Australia were prospectively entered into 
a database (FileMaker Pro, Version 8; FileMaker Inc., Santa 
Clara, CA, USA). For this study, all patients who underwent 
nonsurgical treatment for esophageal cancer over a seven-
year period from March 2001 until February 2008 were 
identified and their outcome was retrospectively determined. 
Patients presenting with tumors of the proximal stomach and 
gastroesophageal junction were excluded.
Patients were not considered for surgical resection if any of 
the following criteria were met: metastatic cancer, significant 
comorbidity (cardiac, pulmonary, renal, or hepatic) which 
precluded esophagectomy, age 80 years or older, or patient 
refused surgery. The decision regarding operability was made 
by a multidisciplinary group, consisting of surgeons, radiation 
oncologists, and medical oncologists. Some patients were 
managed with an esophageal stent, although our preference 
was to use CRT or RT for treatment unless contraindicated. 
Metastasis was defined according the UICC TNM classification 
(6th edition). Metastasis in the celiac lymph nodes from tumors 
of the lower esophagus were considered to be M positive 
(M1a). In tumors of the upper third of the esophagus, metastasis 
to the cervical lymph nodes was considered to be M positive 
(M1a). Patients with UICC stage IV were classified into the 
metastatic group, whereas patients with UCC stages I–III were 
classified into the nonmetastatic group. We did not further 
stratify the nonmetastatic group according lymph node status as 
the resulting cohorts were too small for meaningful analysis.
All patients were staged with computed tomography 
scans (chest and abdomen) and upper endoscopy with biopsy. 
Endoscopic ultrasound was readily available at only one of 
the two treatment sites, and therefore used for staging in only 
37 patients. From 2002, positron emission tomography was 
also readily available at only one of the two treatment sites, 
and it was used for clinical staging in 36 of the patients.
Demographic details, comorbidity, tumor pathology, 
clinical outcome such as palliation, morbidity, and mortality 
were obtained from the database. All data was verified and any 
missing data retrieved from the case records. Treatment-elated 
morbidity was defined as hepatic (increase of liver function 
tests; alanine aminotransferase 50 iU/l, aspartate aminotrans-
ferase 40 iU/l and gamma-glutamyl transferase 60 iU/l), 
renal, radiation esophagitis, neutropenia requiring treatment and 
others such as thrombosis or nausea. Dysphagia was defined as 
the clinical symptom of difficulty to swallow. Clinical follow-
up after treatment was performed by the medical oncologists. 
However, after transfer of care to palliative care, this follow-up 
normally stopped. Survival data was obtained from the South 
Australia State Cancer Registry and the South Australia State 
Births, Deaths and Marriages Registry.
nonsurgical treatment protocols
Localized esophageal cancer was defined as disease that 
could be treated using a single RT field and was UICC stage 
I–III. The standard treatment for these patients was combined 
CRT. RT was given at a dose of 1.8 Gy per fraction once per 
day, to a total of 50.4 Gy, depending on tolerance. The CT, Clinical and Experimental Gastroenterology 2009:2 77
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consisted of cisplatin administered at a dose of 80 mg/m2 over 
one hour with a standard cisplatin hydration protocol, and a 
96-hour infusion of 5-FU administered at 1000 mg/m2 per 
24 hours. CT was administered during week 1 and week 5 
of the RT course. Patients that were able to tolerate further 
CT were treated with two additional courses of CT after the 
completion of RT, in keeping with the RTOG protocol.4 
These courses were usually given at week 9 and week 13 of 
the overall treatment period.
For patients who were not considered suitable for CT, 
RT alone was administered. The most common reasons for 
unsuitability were poor renal function, other comorbidities, 
poor performance status, and patient preference. In 12 patients 
(9.5%) RT alone at a dose of 2 Gy per fraction with a total 
60 Gy over a six-week period was administered.
In general, patients with metastatic disease also 
received combined CRT treatment. The CT involved either 
cisplatin (75–80 mg/m2) and 5-FU (96-hour infusion at 
800–1000 mg/m2 per 24 hours) or epirubicin 50 mg/m2 on 
day 1, cisplatin 60 mg/m2 on day 1 and 5-FU 200 mg/m2 as 
a continuous infusion, with cycles repeated every 21 days 
(ECF).17 In 12 patients (23%), CT alone was given.
As these treatments varied, a subgroup analysis of all 
patients who received the standard combined CRT protocol 
was performed.
statistical analysis
Survival data was determined from records in the database, the 
South Australian Cancer Registry and the South Australian 
Registry of Births, Deaths and Marriages. Comparison of 
data between the two patient groups was undertaken using 
Chi-square tests for categorical data, and Mann–Whitney 
U tests for nonparametric continuous data sets. Survival 
was calculated according to the Kaplan–Meier method, and 
survival differences between groups were determined using 
the log rank test. Statistical significance was set at p  0.05. 
Statistical analyses were performed with MedCalc® (Version 
9 for Windows; MedCalc Software, Mariakerke, Belgium).
This study was approved by the Flinders Clinical 
Research Ethics Committee, and the Royal Adelaide Hospital 
Clinical Research Ethics Committee.
Results
Demographics
Between March 2001 and February 2008, 149 patients under-
went nonsurgical treatment using CT and/or RT, and had 
details entered into the database. Twenty-two (14.8%) of these 
patients were subsequently excluded from analysis because 
the data available was insufficient for analysis. This meant that 
127 patients were included in this study. Of these patients, sur-
vival could not be determined in five (3.9%), as they were lost to 
follow up. Seventy-five (59.1%) were treated for localized dis-
ease and 52 (40.9%) had metastases at the time of treatment.
Within the group with localized disease, 48 patients 
(64%) were considered to be unfit for surgery due to either 
comorbidities (44 patients, 58.7%) or age (eight patients, 
10.7%). Seven patients (9.3%) had a tumor which was 
deemed to be locally unresectable based on imaging criteria 
and 16 (21.3%) refused esophagectomy. Of the patients 
refusing surgery, eight had a locally advanced tumor. There 
were no early stage (T1 or T2) tumors in this group; all 
patients were T-stage 3 or 4. The median patient age was 
higher in the group without metastases, but otherwise the 
demographic data in the groups with and without meta-
static disease were similar (Table 1). Age was significantly 
different between groups. A Cox regression analysis showed 
that age (65 years versus 65 years) was not a predic-
tive factor for survival (hazard ratio 0.72, 95% confidence 
interval: 0.47–1.10; p = 0.132).
Overall, 114 (89.8%) patients had dysphagia at the time 
of diagnosis, 33 (26%) patients had pain, and 11 (8.7%) 
patients had hemorrhaged from the tumor. There were signifi-
cant differences between the groups with metastatic versus 
localized disease for the proportion of patients with pain, and 
the success of the palliation following treatment (Table 2). 
Patients receiving only CT without RT (n = 28) had similar 
rates of pretreatment dysphagia (85.7%). Dysphagia was less 
palliated with CT alone, with only 11.8% of patients having 
a complete palliation, 52.9% a partial palliation and 35.3% 
no palliation. Three of the patients (10.7%) treated with CT 
alone were stented and no patient required dilatations.
Location of metastases
Concerning the location of distant metastases at the time of 
treatment, the liver was affected most frequently (20 patients), 
followed by extra-regional lymph nodes (17 patients), lungs 
(nine patients), and bone (seven patients). One patient had 
metastases in the adrenal gland, one in the peritoneal cavity, 
and one in to the bowel. In six patients, localization of distant 
metastasis could not be determined at review.
nonoperative treatment regimens
Eighty-seven (68.5%) patients received CRT. Twenty-eight 
(22%) received only CT, and 12 (9.5%) only RT. There were 
significant differences in the distribution of treatment types 
between the groups with versus without metastatic disease, Clinical and Experimental Gastroenterology 2009:2 78
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with no patients with metastases receiving RT alone. Other 
interventions performed subsequent to CT and/or RT were 
stenting, dilatation, and feeding jejunostomies. The details 
of these treatments, including CT or RT-related morbidity 
and mortality are summarized in Table 3.
survival
Kaplan–Meier survival analysis showed a median survival of 
10.8 months for the total population. There was a significant 
difference in survival (p  0.001) between the groups with 
versus without metastases, with a median survival in the 
group without metastases of 13.6 months versus 6.5 months 
in the group with metastases (Figure 1). No difference 
between histological subtypes were found (median survival 
for adenocarcinoma 10.8 months and for SCC 11.7 months, 
log rank test; p = 0.507).
The five-year survival for patients undergoing treatment 
for localized disease was 12%.
Table 1 Descriptive parameters of all patients undergoing nonsurgical treatment
Nonmetastatic n = 75 Metastatic n = 52 p
Median age at diagnosis (range) 76.3 (46.3–90.6) 64.8 (32.8–87.8) 0.001*
Gender 0.224
  Male 51 (68.0%)  29 (55.8%) 
  Female 24 (32.0%) 23 (44.2%)
Median BMi (range) 23.8 (15.0–42.9) 25.5 (15.0–32.0) 0.414
Comorbidity
  Cardiac 0.511
    Yes 33 (44.0%) 19 (36.5%)
    no 42 (56.0%) 33 (63.5%)
  Pulmonary 0.117
    Yes 20 (26.7%) 7 (13.5%)
    no 55 (73.3%) 45 (86.5%)
  hepatic 0.674
    Yes 3 (4.0%) 2 (3.8%)
    no 72 (96.0%) 50 (96.2%)
  Renal 0.772
    Yes 5 (6.7%) 2 (3.8%)
    no 70 (93.3%) 50 (96.2%)
  Diabetes 0.566
    Yes 13 (17.3%) 12 (23.1%)
    no 62 (82.7%) 40 (76.9%)
histological type 0.794
  Adenocarcinoma 42 (56.0%) 29 (55.8%)
  squamous cell carcinoma 30 (40.0%) 22 (42.3%)
  Other 3 (4.0%) 1 (1.9%)
Tumor location 0.826
  Upper third 5 (6.7%) 3 (5.8%)
  Middle third 14 (18.7%) 12 (23.1%)
  Lower third 56 (74.6%) 37 (71.1%)
Percentage of circumference involved 0.110
  0%–25% 6 (8.0%) 0 (0.0%)
  25%–50% 5 (6.7%) 2 (3.8%)
  50%–75% 5 (6.7%) 6 (11.6%)
  75%–100% 42 (56.0%) 36 (69.2%)
  no information 17 (22.6%) 8 (15.4%)  
Abbreviation: BMi, body mass index.Clinical and Experimental Gastroenterology 2009:2 79
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There was no survival difference for different histological 
subtypes within the group without metastases (Figure 2), with 
a median survival of 13.1 months in patients with adenocar-
cinoma versus 14.5 months in those with SCC (p = 0.897).
Patients with metastases had no five-year survival. The 
survival analysis stratified according to histological type 
is shown in Figure 3. No significant differences between 
adenocarcinoma and SCC were identified. Median survival 
for patients with adenocarcinoma was 6.2 months compared 
to 9.3 months in patients with SCC (p = 0.429). Survival was 
similar for patients with metastases to distant sites versus 
nonregional lymph nodes and five-year survival was 0 in 
both subgroups. Median survival for patients with distant 
metastasis was 6.5 months compared to 7.7 months in patients 
with nonregional lymph-node metastasis (p = 0.847).
subgroup analysis of patients  
who received combined CRT treatment
Eighty-seven (68.5%) patients received combined CRT 
therapy. The details for these patients are shown in Table 4. 
Except for age, which was again significantly higher in 
the group without metastases, the data was similar to the 
overall group. The median survival for patients without 
metastases was 13.6 months versus 6.5 months in patients 
with metastases (p  0.001) and with five-year survival of 
0% and 12.2%, respectively. Subgroup analysis stratified 
according the histological subtype showed no survival 
difference between the groups with versus without 
metastases. The results were similar to the overall group 
of patients, with median survival times of 5.9 months for 
adenocarcinoma and 6.5 months for SCC (p = 0.515) in the 
group with metastases and 12.5 months for adenocarcinoma 
and 15.2 months for SCC (p = 0.688) in the group without 
metastases.
Discussion
The majority of patients presenting with esophageal cancer 
do not undergo surgical resection, either because they have 
metastatic disease at presentation, or they are unsuitable for 
surgery because of age, co-morbidity, or locally invasive 
disease. Many studies have been published which address 
the use of CT with or without RT in such patients. However, 
the outcomes of various studies vary considerably, because 
of the treatment regimens evaluated, different tumor stages 
treated, the proportion of patients with metastatic disease, and 
the histopathological subtypes treated. Additionally, many 
studies report only a modest number of patients, and are 
reports of initial experience with novel CT regimens, rather 
than reports of outcomes using the conventional treatments 
which are applied in day to day clinical practice.4,5,7–13,18–20 
Furthermore, previous studies fail to stratify outcomes for 
metastatic versus nonmetastatic esophageal cancer in patients 
undergoing nonsurgical treatment. Such stratification allows 
the outcome of two distinct clinical presentations to be 
determined. As presence of metastases is one of the major 
predictors for survival, grouping according to the presence 
or absence of metastatic disease at diagnosis makes sense, 
and knowing the outcome for these scenarios allows surgeons 
to convey to patients accurate information about treatment 
outcomes.14,15
There was a significant age difference between the 
study groups, with patients with metastatic disease being 
younger. However, age was not a prognostic indicator for 
death. Possible explanations for this finding might be that 
cancer is more aggressive when it develops in younger 
patients, or the fact that younger patients with nonmetastatic 
disease were more likely to receive surgical treatment in 
our institutions.
Table 2 symptoms and results of palliation of all patients (n = 127)
Nonmetastatic 
n = 75
Metastatic 
n = 52
p
Dysphagia
  Yes 64 (85.3%) 50 (96.2%) 0.093
  no 11 (14.7%) 2 (3.8%)
Palliation of dysphagia 0.036
  Completely 22 (34.3%) 10 (20.0%)
  Partial 19 (29.7%) 22 (44.0%)
  no palliation 6 (9.4%) 12 (24.0%)
  no information 17 (26.6%) 6 (12.0%)
Pain 0.040
  Yes 14 (18.7%) 19 (36.5%)
  no 61 (81.3%) 33 (63.5%)
Palliation of pain 0.011
  Completely 6 (42.9%) 3 (15.8%)
  Partial 0 (0.0%) 6 (31.6%)
  no palliation 0 (0.0%) 3 (15.8%)
  no information 8 (57.1%) 7 (36.8%)
Bleeding 0.998
  Yes 6 (8.0%) 5 (9.6%)
  no 69 (92.0%) 47 (90.4%)
Palliation of bleeding 1.00
  Completely 6 (100.0%) 5 (100.05)
  Partial 0 (0.0%) 0 (0.0%) 
  no palliation 0 (0.0%) 0 (0.0%)
  no information 0 (0.0%) 0 (0.0%)  Clinical and Experimental Gastroenterology 2009:2 80
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In our study, the majority of patients (68%) received 
treatment with 5-FU and cisplatin, combined with RT of 
50.4 Gy. This is probably the commonest CRT treatment 
regimen currently used in Australia for the treatment of 
patients with esophageal cancer who are not undergoing 
surgical resection. In the group without metastatic disease, 
21% received CT alone (also 5-FU and cisplatin), and 16% 
of patients received RT alone. In the group with metastatic 
disease, all patients in this study received CT, and most (77%) 
in combination with RT. Whilst this variability of treatment 
Table 3 Treatment parameters of all patients (n = 127)
  Nonmetastatic n = 75 Metastatic n = 52 p
Type of therapy 0.0097
  Chemotherapy alone 16 (21.3%) 12 (23.1%)
  Radiotherapy alone 12 (16.0%) 0 (0.0%)
  Combined 47 (62.7%) 40 (76.9%)
Chemo- or radiotherapy-related morbidity 0.422
    Yes 28 (37.3%) 15 (28.8%)
    no 47 (62.7%) 37 (71.2%)
  hepatic 2 1
  Renal 1 0
  Radiation esophagitis 20 12
    neutropenia requiring treatment 2 1
  Other 3 1
Chemo- or radiotherapy-related mortality 0.747
    Yes 2 (2.7%) 1 (1.9%)
    no 73 (97.3%) 51 (98.1%)
stenting undertaken later 0.566
    Yes 13 (17.3%) 12 (23.1%)
    no 62 (82.7%) 40 (76.9%)
Dilatation undertaken later 0.329
    Yes 11 (14.7%) 12 (23.1%)
    no 64 (85.3%) 40 (76.9%)
Feeding jejunostomy undertaken later 0.384
    Yes 9 (12.0%) 10 (19.2%)
    no 66 (88.0%) 42 (80.8%)  
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regimes is a potential source of bias in this study, the variation 
in actual treatments reflects clinical practice rather than a 
clinical trial protocol, and the results of our study still inform 
clinical decision making. Furthermore, the subgroup analysis 
which compared the outcome for patients who received 
combined CRT with patients who had monotherapy (CT or 
RT alone) revealed similar survival outcomes.
Not surprisingly, we saw a significant difference in 
survival outcomes for patients with metastatic versus non-
metastatic esophageal cancer. The five-year survival for 
patients presenting with localized disease was 12%, whereas 
almost no patients with metastases survived for five years. 
These data are comparable with other reports of patients 
undergoing definitive CRT.6,18 Furthermore, all patients 
with localized disease had poor prognosis T-stage T3 or 
T4 tumors at presentation, and this survival data should be 
considered when discussing with patients the pros and cons 
of surgical resection for advanced esophageal cancer. The 
outcome of definitive CRT in patients with nonmetastatic 
tumors is almost certainly inferior to multimodal treatment 
which includes surgery, where five-year survival rates 
over 30% have been reported, although direct comparisons 
between studies can be difficult, as post-surgical survivals 
in most series are almost certainly favorably influenced by 
the inclusion of some patients with earlier stage disease.21–24 
Two recent studies evaluating CRT with or without surgery 
have suggested no benefit for multimodal treatment includ-
ing surgery.25,26 However, these studies have only evalu-
ated SCC. One of these studies only determined two-year 
survival, and whilst the other reported equivalent overall 
survival, local progression-free survival was better following 
surgery, and surgery was associated with a significantly lower 
treatment-related mortality outcome.24,26
Treatment-related morbidity was significant, being 34% 
in our study. Treatment-related mortality was 2.4%, and 
this is comparable to other series which report morbidity 
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Table 4 Descriptives of the subgroup of patients who underwent 
combined chemoradiotherapy (n = 87)
Nonmetastatic 
n = 47
Metastatic 
n = 40
p
Median age at 
diagnosis (range)
75.9 (46.3–90.6) 66.5 (32.8–87.8) 0.001
Gender 0.083
  Male 33 24
  Female 14 16
Comorbidity
  Cardiac 0.112
    Yes 24 15
    no 23 25
  Pulmonary 0.083
    Yes 14 6
    no 33 34
  hepatic 0.315
    Yes 3 1
    no 44 39
  Renal 0.817
    Yes 2 2
    no 45 38
  Diabetes 0.071
    Yes 9 11
    no 38 29
histological type 0.604
  Adenocarcinoma 25 22
    squamous cell 
carcinoma
20 18
  Other 2 0
Tumor location 0.825
  Upper third 4 2
  Middle third 11 11
  Lower third 32 27
Chemo- or 
radiotherapy- 
related morbidity
0.704
    Yes 17 12
    no 30 28
Chemo- or 
radiotherapy- 
related mortality
0.547
    Yes 1 1
    no 39 46  Clinical and Experimental Gastroenterology 2009:2 82
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and mortality rates of 4.0% and 3.5%, respectively.27–29 
These mortality rates are not significantly lower than for 
patients undergoing esophagectomy, although patients 
undergoing surgery, are on average likely to be fitter than 
those who are refused surgery because of co-morbidity, and 
hence morbidity and mortality cannot be validly compared. 
Nevertheless, the data do highlight the risks of nonsurgical 
treatment.30
Pre-treatment dysphagia was present in a majority of 
patients, and more frequently than previously described.2 
Dysphagia was not assessed with a score. All patients had 
clinical follow-up after treatment by the medical oncologists, 
but this usually stopped when the care was transferred to 
palliative care. This might have resulted in under-reporting 
of post-treatment dysphagia, especially when dysphagia 
reoccurred and patients were under the care of the palliative 
team. Almost all patients with metastatic tumors reported 
dysphagia. Palliation of dysphagia with RT/CT was less 
often achieved in patients with metastatic disease, and pain 
was also more frequent in these patients and less often pal-
liated. Also, CT alone was less effective for the palliation 
of dysphagia than combination treatment, highlighting the 
importance of RT in patients who present with dysphagia. 
However, in this cohort omission of RT did not result in a 
higher number of patients requiring stenting or dilatation.
A number of the patients needed additional interven-
tions such as an esophageal stent, endoscopic dilatation, or 
feeding jejunostomy. The likelihood of needing one of these 
interventions was not influenced by presence or absence of 
metastatic disease at the time of treatment. RT/CT achieves 
good palliation of tumor related symptoms.31,32 Our results 
suggest that excellent palliation of dysphagia was achieved 
in most patients and only a minority subsequently required 
palliation with an endoscopic stent.
Conclusion
Patients with esophageal cancer who do not undergo 
esophagectomy will usually benefit from CRT, supported by 
interventions such as stenting and dilatation. Nevertheless, 
treatment related morbidity is not insubstantial. In patients 
with localized disease at diagnosis, long term survival can 
be achieved in approximately 12% of patients, whereas five-
year survival is very rare in patients with metastatic disease 
at presentation.
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